Sahajanand Medical Technologies Ltd. — Q2 FY27 — 5 November 2026

1. Overall Tone of Management

Optimistic, but measured. Management highlighted record revenue, EBITDA and PAT, operating leverage, and a multi-year margin target. However, headline growth was materially helped by currency (24.7% reported versus about 16% constant currency), gross margin declined year-on-year, and management declined to quantify several items, including capacity potential and the gross-margin benefit from integration.

2. Key Themes from Management Commentary

• Growth was broad-based, with currency support: Q2 revenue rose 24.7%; constant-currency growth was about 16%. Growth came across product categories and regions. H1 ROW growth was 37%, Europe 23%, while India improved from 6% in Q1 to 15% in Q2.
• Operating leverage is the central earnings driver: EBITDA grew faster than revenue as employee and other expense ratios declined. Management attributed this partly to sales teams already built in Europe and the ability to sell more products through existing channels.
• Mix is pressuring gross margin: H1 gross margin fell about 170 bps year-on-year; management attributed roughly 150 bps to product and regional mix, with the balance from input and labor costs. Traded products, especially IVUS, are growing quickly and dilute gross margin, though management says they are EBITDA-accretive.
• Structural heart and new products are growth priorities: Structural heart grew about 40% in Q2. Management expects it to grow faster than vascular intervention, while continuing launches in drug-coated balloons, TAVI, and PTCA products.
• Capacity and working capital: Telangana has significant headroom, and management expects growth without a proportionate increase in capex. Cash conversion cycle improved to 128 days; further inventory improvement is a stated focus.
• Listed-company accountability: Management said it intends to report consistent KPIs each quarter so investors can track commitments.

3. Q&A Analysis

Growth, currency and capacity

• Questions: What is FY27 growth guidance in constant currency? How much revenue could current and planned capacity support?
• Response: Management indicated mid-teens constant-currency growth for FY27, with mid-teens as a conservative baseline for FY28 as well. Existing capacity is expected to be sufficient for at least 1.5 years; capex is not expected to exceed about ₹70 crore annually for 2–3 years.
• Evasiveness / signal: Management would not quantify peak revenue capacity, saying current capex is primarily for vertical integration and capabilities, not simply adding revenue capacity. It offered to revisit the question.

Margins, capex and costs

• Questions: Can vertical integration lift gross margin? What are steady-state EBITDA margins? What are capex and tax expectations?
• Response: Vertical integration should improve gross margins, but management would not quantify the benefit until processes are established and tested. It guided to 150–200 bps annual EBITDA-margin improvement through FY29, reaching around 20%. FY27 capex is about ₹70 crore, with a similar annual level indicated for FY28; spend includes integration, automation, maintenance and some capacity enhancement. ETR is expected at 32–35% for 2–3 years.
• Strong answer: The multi-year EBITDA-margin target is explicit. Partial answer: The gross-margin contribution from integration remains unquantified.

Product pipeline and regulatory approvals

• Questions: What is the status of MDR certifications and upcoming launches?
• Response: SupraFlex Cruz is certified; other product families are in the audit or application process, with management confident of meeting the end-2027 transition deadline. TAVI 2.0 and AVDC were expected within FY27, potentially Q3 and no later than Q4. PTCA catheters were indicated for FY28; later pipeline products are 2–3 years away.
• Signal: Management gave time windows, but described the later pipeline only in broad terms. Products due within six months were in technology transfer, with approvals received.

Working capital and product mix

• Questions: How much further can working-capital days fall, and which segment should grow faster?
• Response: Management expects about 15 days of further improvement over three years, to roughly 100–110 days from 128, primarily through lower inventory. Structural heart is expected to grow faster than vascular intervention, given its smaller base and larger, faster-growing market.
• Signal: The working-capital target is specific, though the stated range is not perfectly aligned with a 15-day reduction from 128 days.

Europe and commercial execution

• Questions: Can the existing European sales force support structural-heart growth? What is SMT’s TAVI position?
• Response: The same sales force serves vascular and structural-heart products; a smaller clinical-specialist team supports complex products such as TAVI. Management put European TAVI share at about 1.5%, below 2%, and sees newer-generation devices supporting faster traction.
• Notable admission: Management was direct that TAVI remains a small-share, relatively new business in Europe.

India regulation, utilization and country count

• Questions: Will the single-use medical-device notification materially boost India growth? Why did utilization and invoiced-country counts decline?
• Response: Management sees the notification as a tailwind, but said affected products are a smaller part of its portfolio and rejected the idea that it would lift industry growth from 9–10% to 15–20%. Lower PTCA utilization was attributed to inventory optimization. The country count reflects countries invoiced in the quarter and can fluctuate with distributor buying patterns.
• Signal: The response tempered the apparent regulatory upside and clarified that the quarterly country KPI is not equivalent to presence or market exit.

Traded products and IVUS

• Questions: What explains the rise in traded products, how large is IVUS, and could an acquisition affect the thrombectomy business?
• Response: Management attributed much of the trading growth to IVUS demand following reimbursement changes in developed markets. It said trading dilutes gross margin but is EBITDA-accretive because SG&A is shared, and reiterated that developing and selling its own products remains the priority.
• Evasiveness: It declined to provide product-level revenue detail, including the IVUS contribution. The specific potential impact of the cited thrombectomy acquisition was not clearly addressed.

4. Guidance / Outlook

Quantitative guidance

• Revenue: Mid-teens constant-currency growth for FY27; mid-teens as a conservative baseline for FY28. Reported growth may differ with currency.
• EBITDA margin: Improvement of 150–200 bps annually through FY29, targeting around 20% by FY29.
• Capex: About ₹70 crore in FY27, with a similar level indicated for FY28 and no meaningful increase expected for 2–3 years.
• Working capital: Around 15 days of further improvement over three years, targeting approximately 100–110 days from 128.
• Tax: ETR expected at 32–35% for the next 2–3 years.
• R&D: Spend expected to remain around 9–10% of revenue, fully expensed.
• Product timing: TAVI 2.0 and AVDC expected within FY27; PTCA catheter launches indicated for FY28.
• Seasonality: H2 typically contributes about 52% of annual revenue versus 48% in H1.

Qualitative signals

• Structural heart is expected to grow faster than vascular intervention.
• Telangana utilization should rise, allowing revenue growth on an existing asset base.
• European hiring should be limited because teams are already in place; salary growth is expected to track local inflation of 3–5%.
• Vertical integration should help gross margins, but management withheld an estimate until the processes are established.
• Further working-capital improvement is expected to come mainly from inventory.

5. Standout Statements

• “We intend to report transparently and consistently on the same KPIs every quarter.”
• “This year, next year, and perhaps the year after next as well, we will deliver 150–200 basis points of EBITDA margin improvement every year.”
• On currency: “Reported currency will be difficult for us to guide.”
• On India’s single-use tailwind: “I do not think the jump in industry growth will be that significant.”
• On Europe’s TAVI business: market share is “somewhere around 1.5%” and “we have not yet crossed 2%.”
• On traded products: “Although the trading business dilutes gross margin, SG&A is common, so at the EBITDA level it is highly accretive.”

6. Red Flags / Positive Signals

Red flags
– Reported growth materially exceeded constant-currency growth, making FX a meaningful contributor this period.
– Gross margin declined despite strong EBITDA-margin expansion; favorable operating leverage may not fully offset mix and input-cost pressure indefinitely.
– Management did not quantify peak revenue capacity, integration benefits to gross margin, or product-level traded revenue.
– Current Q2 margin of 17.6% is well above the H1 margin of 15.7%; the FY29 target should be assessed against full-year results rather than extrapolated from one quarter.

Positive signals
– EBITDA grew faster than revenue in Q2 and H1, with lower employee and other expense ratios.
– Structural heart growth accelerated; management cited a ready commercial network for cross-selling in Europe.
– Telangana and existing facilities offer room to grow without a large near-term capex step-up.
– Cash-conversion metrics and return ratios improved.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

The three prior transcripts are marked “Transcript Not Available.” Their dates, periods, tone and themes cannot be verified, so no quarter labels or historical tone shifts can be assigned without inventing information.

Prior call — transcript unavailable
– Dominant tone: Not assessable
– Major themes this quarter: Not available
– Tone shift vs previous quarter: Not assessable
– What changed: No transcript supplied.

Second-prior call — transcript unavailable
– Dominant tone: Not assessable
– Major themes this quarter: Not available
– Tone shift vs previous quarter: Not assessable
– What changed: No transcript supplied.

Third-prior call — transcript unavailable
– Dominant tone: Not assessable
– Major themes this quarter: Not available
– Tone shift vs previous quarter: Not assessable
– What changed: No transcript supplied.

Q2 FY27
– Dominant tone: Optimistic
– Major themes this quarter:
– Record quarterly financial performance and operating leverage.
– Margin expansion despite weaker gross margin from mix and costs.
– Product launches, MDR progress and structural-heart growth.
– Telangana utilization and working-capital improvement.
– Tone shift vs previous quarter: N/A — prior transcript unavailable.
– What changed: This is management’s first earnings call as a listed company; it explicitly promised consistent KPI reporting and gave multi-year margin guidance.

Trajectory Summary: The available record begins with Q2 FY27, so a multi-quarter tone trajectory cannot be established. This call combines strong current results and explicit margin ambitions with selective caution on FX, capacity, and the timing and magnitude of gross-margin benefits.

b. Tracking Past Commitments vs Outcomes

The prior transcripts needed to verify earlier commitments were not provided. The current call does reference earlier pipeline commentary:

• Past statement: Earlier calls reportedly discussed 2–3 products in the pipeline over the next 2–3 years.
• What was expected: Development progress and launches over that period.
• What management now says: Products are “progressing as planned”; near-term launches are in technology transfer, FY28 PTCA products are in regulatory approval, and later products remain under development.
• Flag: Not yet due / progress stated, but independently unverified against the unavailable prior calls.

c. Narrative Shifts

Unable to confirm shifts against prior transcripts. Within this call, the clearest emphasis is on operating leverage and margin expansion, while management also acknowledged faster growth in lower-gross-margin traded products. It maintained that own-product development remains the strategic priority.

d. Consistency & Credibility Signals

Overall credibility: Medium — limited evidence. Management gave specific growth, margin, capex and working-capital outlooks, and acknowledged gross-margin pressure and low European TAVI share. But historical consistency, missed targets and repeated deferrals cannot be tested without prior transcripts. Several important questions—peak capacity and the scale of integration benefits—remain unanswered quantitatively.

e. Evolution of Key Themes

Historical direction cannot be measured from the supplied material. Current-call signals:
– Demand/growth: Positive, though constant-currency growth is below reported growth.
– Margins: Improving at the EBITDA level; gross margin is pressured by mix and costs.
– Expansion: Structural heart and new product launches are priorities.
– Cash/working capital: Improving, with inventory still a focus.
– Regulation: MDR compliance progress and India’s single-use notification are viewed favorably, though the latter’s growth impact is characterized as limited.

f. Additional Insights

• Strong quarterly EBITDA-margin expansion coexists with a lower H1 gross margin, indicating that cost leverage and mix are pulling in opposite directions.
• The reported-growth headline overstates underlying volume growth; constant-currency guidance is the more comparable indicator for tracking performance.
• Management’s commitment to quarterly KPI consistency is especially relevant because country count, utilization and reported-versus-constant-currency growth require careful interpretation.